MTA-Bound PRMT5 Inhibitors for MTAP-Deleted Tumor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PRMT5 inhibitors target both MTAP-deleted tumor cells and normal cells, leading to significant side effects, necessitating the development of selective PRMT5 inhibitors that can target only MTAP-deleted tumors while sparing normal tissues.
Innovation Solution
Development of a series of compounds that selectively inhibit PRMT5 in the MTA-bound state, which is enriched in MTAP-deleted tumor cells, thereby minimizing effects on normal cells with intact MTAP.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 is inhibited in normal tissues, then PRMT5-mediated diseases can be treated, but significant side effects occur (cytopenia, infertility, decreased skeletal muscle, myocardial hypertrophy)
Solution Approach 1:
The patent applies local quality by designing inhibitors with different structural characteristics that selectively bind to PRMT5 in specific cellular contexts (MTAP-deleted cells vs. normal cells). The compounds have tailored chemical properties (e.g., specific functional groups, molecular weight ranges) that enable them to interact differently with PRMT5 depending on the cellular environment, particularly the presence or absence of MTA competition.
Solution Approach 2:
The patent employs parameter changes by modifying key molecular parameters of the inhibitor compounds including molecular weight (150-500 Da), logP values (0.5-3.0), and specific functional group configurations. These parameter adjustments create a gradient of inhibitor potency that correlates with cellular MTA levels, enabling selective inhibition in tumors while sparing normal tissues.
2Productivity
If PRMT5 inhibition is applied broadly, then tumor cells with MTAP deletion can be targeted, but normal cells with intact MTAP are also affected
Solution Approach 1:
The patent uses MTA as an intermediary mechanism. In MTAP-deleted tumor cells, MTA accumulates and competes with the inhibitor for binding to PRMT5, reducing inhibitor efficacy in these cells. This counterintuitive approach actually protects normal cells (which have intact MTAP and thus lower MTA levels) from inhibition while allowing selective targeting of tumors through the metabolic vulnerability created by MTAP deletion.
3Adaptability or versatility
If selective PRMT5 inhibitors are developed for MTAP-deleted tumors, then treatment window is improved, but compound design complexity increases
Solution Approach 1:
The patent segments the inhibitor molecule into distinct functional regions: a core scaffold (various heterocyclic structures), substituent groups (R1-R6 positions), and specific functional moieties (amino, hydroxyl, carbonyl groups). This segmentation allows systematic optimization of each region's contribution to selectivity and potency, simplifying the overall design process despite the need for high selectivity.
Data Source
AI summary
A PRMT5 inhibitor, a preparation method therefor, and the pharmaceutical use thereof. In particular, provided are a PRMT5 inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use of the compound as a PRMT5 inhibitor and for treatment and/or prevention of PRMT5-mediated diseases. Each substituent of formula (I) is as defined in the description.